Orgenesis Inc., a provider of point-of-care cell and gene therapy development, processing and treatment solutions, announced that it has entered into a collaboration agreement with the John Hopkins University. Orgenesis’ labs include development of anti-viral technologies relevant to COVID-19.
Read two recent articles about Orgenesis and Johns Hopkins.